Chromogranins — New Sensitive Markers for Neuroendocrine Tumors
Open accessThe DOI matches its Crossref record.
Abstract
Chromogranins A, B and C, proteins that are costored and coreleased with peptides and amines, have been identified in a variety of endocrine and nervous tissues, both normal and neoplastic. We examined the secretion of chromogranin A and chromogranin A + B by hormone-producing tumors in patients with endocrine pancreatic tumors (EPT), carcinoid tumors, pheochromocytomas and small cell lung cancer (SCLC). Radioimmunoassay (RIA) of the plasma/serum concentrations of chromogranin A + B showed a greater sensitivity than RIA of chromogranin A alone. All patients with EPT, carcinoids and pheochromocytomas had increased levels of chromogranin A + B, whereas a small number of the patients (5/18 with EPT and 1/3 with pheochromocytomas) had normal levels of chromogranin A. Also in immunocytochemical stainings, our polyclonal antiserum detecting both chromogranin A and B showed a greater sensitivity than other available antisera against chromogranin A, B and C.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The clinically inapparent adrenal mass: update in diagnosis and management
Mansmann, G., Lau, J., Balk, E., Rothberg, M., Miyachi, Y., & Bornstein, S. R. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0031 · Cited by 781
“Bcl-2 Malignant pheo Higher expression (285) TGF 1mRNA ACC Reduced (286) Telomerase activity ACC High activity (287, 288) Malignant pheo High activity (289) Ploidy Malignant pheo Non-diploidy commonly present (290, 291) Adrenal 4 binding protein ACC Adrenocortical marker (292) ACTH Malignant pheo Overexpression (293)…”
BackgroundEndocrine tumours of the pancreas
Öberg, K., & Eriksson, B. (2005) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2005.06.002 · Cited by 543
Self-citationChromogranin A—Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease
Modlin, I. M., Gustafsson, B. I., Moss, S. F., Pavel, M., Tsolakis, A. V., & Kidd, M. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1006-3 · Cited by 387
Ekeblad, S., Skogseid, B., Dunder, K., Öberg, K., & Eriksson, B. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0734 · Cited by 360
Self-citationChromogranin A—unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls
Gut, P., Czarnywojtek, A., Fischbach, J., Bączyk, M., Ziemnicka, K., Wrotkowska, E., Gryczyńska, M., & Ruchała, M. (2016) · Archives of Medical Science · doi:10.5114/aoms.2016.57577 · Cited by 144
“Reduction of CgA concentration is used frequently as an indicator of response to treatment in clinical trials, in which the biochemical response is usually defined as a ≥ 50% reduction in the concentration of CgA [33, 44, 46].”
Method
Metadata
- Authors
- Eriksson, B., Arnberg, H., Ouberg, K., Hellman, U., Lundqvist, G., Wernstedt, C., & Wilander, E.
- Venue
- Acta Oncologica
- Published
- 1989-01
- Volume
- 28
- Issue
- 3
- Pages
- 325-329
- ISSN
- 0284-186X (ISSN-L)
- 1651-226X
- OpenAlex
- W2120040732
- Cited by
- 76
- References
- 0
- FWCI
- 1.37
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chromogranins — New Sensitive Markers for Neuroendocrine Tumors. https://app.cochat.ai/papers/10.3109/02841868909111201
- The paper
- Eriksson, B., Arnberg, H., Ouberg, K., Hellman, U., Lundqvist, G., Wernstedt, C., & Wilander, E. (1989). Chromogranins — New Sensitive Markers for Neuroendocrine Tumors. Acta Oncologica. https://doi.org/10.3109/02841868909111201
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.